Clinical Trial Update: Pharmacogenomic Biomarker Study for Recombinant Human Activated Protein C Treatment in Severe Sepsis

View source ↗

Summary

A pharmacogenomic biomarker study is being conducted to evaluate recombinant human activated protein C for treatment in patients with severe sepsis and septic s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis
• Septic Shock

Drugs mentioned

• Drotrecogin alfa (activated) (drotrecogin alfa (activated))

Snippet

Sponsor: Sirius Genomics Inc. | Conditions: Severe Sepsis, Septic Shock | Status: UNKNOWN